MarketPulse

Phase 2b trial

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kymera Therapeutics Lands $45M Milestone as FDA Fast-Tracks Asthma Drug

Kymera Therapeutics receives $45M from Gilead option exercise and FDA Fast Track designation for asthma drug KT-621, with Phase 2b data expected late 2027.
GILDKYMRasthmaGilead Sciences
The Motley FoolThe Motley Fool··Eric Volkman

Nektar Therapeutics Surges 18% on Positive Alopecia Drug Trial Results

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.
NKTRclinical trial resultsbiotech stock
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Radiopharm Theranostics Partners with Siemens on RAD101 PET Imaging Agent for Brain Metastases

Radiopharm Theranostics and Siemens Healthineers sign manufacturing supply agreement for RAD101 PET imaging agent, advancing toward Phase 3 trial with strong interim data.
SMMNYRADXradiopharmaceuticalsPET imaging
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Investigation After Failed Trial Announcement

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.
NKTRshareholder lawsuitstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosures

Law firm Bernstein Liebhard announces class action against $NKTR over alleged misrepresentations regarding Phase 2b trial results, affecting investors from February to December 2025.
PLUGSLNONKTRsecurities fraudclass action lawsuit